Naturally processed HLA class I-restricted epitopes inform targets of protective CD8+ T cell-mediated immunity (113.11)
Pavlo Gilchuk(AstraZeneca (Japan)), Sebastian Joyce(Walther Cancer Foundation), Alessandro Sette(La Jolla Institute for Immunology), Stephanie B. Conant(Vanderbilt University), Xinnan Niu(Vanderbilt University), Charles T. Spencer(The University of Texas at El Paso), John C. Williams(Columbia University), Sine Reker Hadrup(Herlev Hospital), K. Jill McAfee(Vanderbilt University), James E. Crowe(Vanderbilt University Medical Center), William H. Hildebrand(University of Oklahoma Health Sciences Center), John J. Erickson(Vanderbilt University), Andrew J. Link(Vanderbilt University), Kathryn Edwards, Carla Oseroff(La Jolla Institute for Immunology), Ton N. Schumacher(Leiden University Medical Center), Jack R. Bennink(National Institutes of Health), Søren Buus(University of Copenhagen)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
|Cell|2020|4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k